These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 24701200)

  • 1. 2-Methyl-6-(phenylethynyl) pyridine (MPEP) reverses maze learning and PSD-95 deficits in Fmr1 knock-out mice.
    Gandhi RM; Kogan CS; Messier C
    Front Cell Neurosci; 2014; 8():70. PubMed ID: 24701200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative study of the performance of individuals with fragile X syndrome and Fmr1 knockout mice on Hebb-Williams mazes.
    MacLeod LS; Kogan CS; Collin CA; Berry-Kravis E; Messier C; Gandhi R
    Genes Brain Behav; 2010 Feb; 9(1):53-64. PubMed ID: 19796132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Visual-spatial learning impairments are associated with hippocampal PSD-95 protein dysregulation in a mouse model of fragile X syndrome.
    Gandhi RM; Kogan CS; Messier C; Macleod LS
    Neuroreport; 2014 Mar; 25(4):255-61. PubMed ID: 24323121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BDNF in fragile X syndrome.
    Castrén ML; Castrén E
    Neuropharmacology; 2014 Jan; 76 Pt C():729-36. PubMed ID: 23727436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective Deletion of Astroglial FMRP Dysregulates Glutamate Transporter GLT1 and Contributes to Fragile X Syndrome Phenotypes In Vivo.
    Higashimori H; Schin CS; Chiang MS; Morel L; Shoneye TA; Nelson DL; Yang Y
    J Neurosci; 2016 Jul; 36(27):7079-94. PubMed ID: 27383586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Group I metabotropic glutamate receptor antagonists alter select behaviors in a mouse model for fragile X syndrome.
    Thomas AM; Bui N; Perkins JR; Yuva-Paylor LA; Paylor R
    Psychopharmacology (Berl); 2012 Jan; 219(1):47-58. PubMed ID: 21656124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early continuous inhibition of group 1 mGlu signaling partially rescues dendritic spine abnormalities in the Fmr1 knockout mouse model for fragile X syndrome.
    Su T; Fan HX; Jiang T; Sun WW; Den WY; Gao MM; Chen SQ; Zhao QH; Yi YH
    Psychopharmacology (Berl); 2011 May; 215(2):291-300. PubMed ID: 21181121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Matrix metalloproteinase-9 deletion rescues auditory evoked potential habituation deficit in a mouse model of Fragile X Syndrome.
    Lovelace JW; Wen TH; Reinhard S; Hsu MS; Sidhu H; Ethell IM; Binder DK; Razak KA
    Neurobiol Dis; 2016 May; 89():126-35. PubMed ID: 26850918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization and reversal of synaptic defects in the amygdala in a mouse model of fragile X syndrome.
    Suvrathan A; Hoeffer CA; Wong H; Klann E; Chattarji S
    Proc Natl Acad Sci U S A; 2010 Jun; 107(25):11591-6. PubMed ID: 20534533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fragile X mental retardation protein regulates protein expression and mRNA translation of the potassium channel Kv4.2.
    Gross C; Yao X; Pong DL; Jeromin A; Bassell GJ
    J Neurosci; 2011 Apr; 31(15):5693-8. PubMed ID: 21490210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involvement of Phosphodiesterase 2A Activity in the Pathophysiology of Fragile X Syndrome.
    Maurin T; Melancia F; Jarjat M; Castro L; Costa L; Delhaye S; Khayachi A; Castagnola S; Mota E; Di Giorgio A; Servadio M; Drozd M; Poupon G; Schiavi S; Sardone L; Azoulay S; Ciranna L; Martin S; Vincent P; Trezza V; Bardoni B
    Cereb Cortex; 2019 Jul; 29(8):3241-3252. PubMed ID: 30137253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced endocannabinoid signaling elevates neuronal excitability in fragile X syndrome.
    Zhang L; Alger BE
    J Neurosci; 2010 Apr; 30(16):5724-9. PubMed ID: 20410124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. c-Jun N-terminal kinase regulates mGluR-dependent expression of post-synaptic FMRP target proteins.
    Schmit TL; Dowell JA; Maes ME; Wilhelm M
    J Neurochem; 2013 Dec; 127(6):772-81. PubMed ID: 24047560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of Serotonin 5-HT
    Costa L; Sardone LM; Bonaccorso CM; D'Antoni S; Spatuzza M; Gulisano W; Tropea MR; Puzzo D; Leopoldo M; Lacivita E; Catania MV; Ciranna L
    Front Mol Neurosci; 2018; 11():353. PubMed ID: 30333723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic manipulation of STEP reverses behavioral abnormalities in a fragile X syndrome mouse model.
    Goebel-Goody SM; Wilson-Wallis ED; Royston S; Tagliatela SM; Naegele JR; Lombroso PJ
    Genes Brain Behav; 2012 Jul; 11(5):586-600. PubMed ID: 22405502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dysregulated NMDA-Receptor Signaling Inhibits Long-Term Depression in a Mouse Model of Fragile X Syndrome.
    Toft AK; Lundbye CJ; Banke TG
    J Neurosci; 2016 Sep; 36(38):9817-27. PubMed ID: 27656021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subchronic administration and combination metabotropic glutamate and GABAB receptor drug therapy in fragile X syndrome.
    Pacey LK; Tharmalingam S; Hampson DR
    J Pharmacol Exp Ther; 2011 Sep; 338(3):897-905. PubMed ID: 21636656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fragile X mental retardation protein deficiency leads to excessive mGluR5-dependent internalization of AMPA receptors.
    Nakamoto M; Nalavadi V; Epstein MP; Narayanan U; Bassell GJ; Warren ST
    Proc Natl Acad Sci U S A; 2007 Sep; 104(39):15537-42. PubMed ID: 17881561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative proteomics of forebrain subcellular fractions in fragile X mental retardation 1 knockout mice following acute treatment with 2-Methyl-6-(phenylethynyl)pyridine: Relevance to developmental study of schizophrenia.
    Folsom TD; Higgins L; Markowski TW; Griffin TJ; Fatemi SH
    Synapse; 2019 Jan; 73(1):e22069. PubMed ID: 30176067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in sensitivity of reward and motor behavior to dopaminergic, glutamatergic, and cholinergic drugs in a mouse model of fragile X syndrome.
    Fish EW; Krouse MC; Stringfield SJ; Diberto JF; Robinson JE; Malanga CJ
    PLoS One; 2013; 8(10):e77896. PubMed ID: 24205018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.